Avery Dennison (NYSE:AVY) reported quarterly earnings of $2.13 per share which beat the analyst consensus estimate of $2.12 by 0.47 percent. This is a 6.17 percent decrease over earnings of $2.27 per share from the same period last year. The company reported quarterly sales of $2.20 billion which beat the analyst consensus estimate of $2.12 billion by 3.77 percent. This is a 10.50 percent increase over sales of $1.99 billion the same period last year.
NeuBase Therapeutics Reports Business Update And Financial Results For Q1 Of FY23; As Of December 31, 2022, The Company Had Cash And Cash Equivalents Of ~$17.4M
NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision
